Opiant Pharmaceuticals, Inc. Common Stock
OPNT
OPNT was delisted on the 1st of March, 2023.
16 hedge funds and large institutions have $1.93M invested in Opiant Pharmaceuticals, Inc. Common Stock in 2018 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 3 closing their positions.
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
14% more funds holding
Funds holding: 14 → 16 (+2)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
11% less capital invested
Capital invested by funds: $2.16M → $1.93M (-$228K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
+$429K |
| 2 |
BlackRock
New York
|
+$118K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$66.6K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$62.4K |
| 5 |
GI
Gradient Investments
Arden Hills,
Minnesota
|
+$6.16K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SIM
Spark Investment Management
New York
|
-$191K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$65K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$33.7K |
| 4 |
OSAM
O'Shaughnessy Asset Management
Stamford,
Connecticut
|
-$17.3K |
| 5 |
IWM
IHT Wealth Management
Chicago,
Illinois
|
-$5K |
OPNT Hedge Fund Activity: Q2 2018 in Review
16 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Opiant Pharmaceuticals, Inc. Common Stock (OPNT) for Q2 2018, worth a combined $1.93M — down 11% from $2.16M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new OPNT positions and 3 closed out — a net gain of 2 holders — while 3 added to existing stakes and 3 trimmed.
The largest buyer was Northern Trust, opening a new position worth an estimated $429K. The largest seller was Spark Investment Management, exiting entirely with an estimated $191K sold.
- 16 institutional investors held Opiant Pharmaceuticals, Inc. Common Stock (OPNT) as of Q2 2018, up from 14 in Q1 2018.
- Funds reported $1.93M of Opiant Pharmaceuticals, Inc. Common Stock stock for Q2 2018, down 11% quarter-over-quarter.
- 5 funds opened new Opiant Pharmaceuticals, Inc. Common Stock positions in Q2 2018 and 3 closed out, a net change of +2 holders.
- The largest Opiant Pharmaceuticals, Inc. Common Stock buyer in Q2 2018 was Northern Trust, an estimated $429K added.
- The largest Opiant Pharmaceuticals, Inc. Common Stock seller in Q2 2018 was Spark Investment Management, an estimated $191K sold.
Based on aggregated 13F filings for Q2 2018.